Logo Image

Neil M. Iyengar, MD

Articles by Neil M. Iyengar, MD

5 experts are featured in this series

SABCS Highlights and Future Directions in the Treatment of Breast Cancer

ByNeil M. Iyengar, MD,Sara A. Hurvitz, MD, FACP ,Laura Huppert, MD,Anne P. O’Dea, MD,Melinda L. Telli, MD

Panelists discuss how the continued evolution of HER2-directed therapies, particularly the expanding role of trastuzumab deruxtecan (T-DXd) across different breast cancer settings, has transformed the treatment landscape, while emphasizing the importance of appropriate patient selection, optimal sequencing strategies, and the need for education around early adoption of promising therapies in community practice settings.

5 experts are featured in this series

Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer

ByNeil M. Iyengar, MD,Sara A. Hurvitz, MD, FACP ,Laura Huppert, MD,Anne P. O’Dea, MD,Melinda L. Telli, MD

Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.

5 experts are featured in this series

Novel and Emerging Strategies for HER2+ Breast Cancer With Brain Metastases

ByNeil M. Iyengar, MD,Sara A. Hurvitz, MD, FACP ,Laura Huppert, MD,Anne P. O’Dea, MD,Melinda L. Telli, MD

Panelists discuss how sequential therapy selection for patients with HER2+ breast cancer with progressive brain metastases requires careful consideration of prior treatments, patterns of progression, symptom burden, and available clinical trials, while balancing the need for both systemic disease control and CNS -specific approaches.

5 experts are featured in this series

Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases

ByNeil M. Iyengar, MD,Sara A. Hurvitz, MD, FACP ,Laura Huppert, MD,Anne P. O’Dea, MD,Melinda L. Telli, MD

Panelists discuss how the DESTINY-Breast12 trial evaluated trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer (mBC) with brain metastases, demonstrating encouraging intracranial responses and overall survival outcomes while maintaining a manageable safety profile consistent with previous T-DXd studies.

5 experts are featured in this series

Precision in CNS Targeting: Optimizing Management of Brain Metastases in HER2+ Breast Cancer

ByNeil M. Iyengar, MD,Sara A. Hurvitz, MD, FACP ,Laura Huppert, MD,Anne P. O’Dea, MD,Melinda L. Telli, MD

Panelists discuss how treatment selection for patients with HER2+ breast cancer with brain metastases requires careful consideration of factors such as metastatic burden, symptomatology, and prior therapies, typically incorporating both local approaches and systemic agents with CNS activity while accounting for individual patient characteristics such as performance status, comorbidities, and preferences in developing personalized treatment plans.

5 experts are featured in this series

Evolving Paradigms in HER2+ Advanced Breast Cancer With Brain Metastases

ByNeil M. Iyengar, MD,Sara A. Hurvitz, MD, FACP ,Laura Huppert, MD,Anne P. O’Dea, MD,Melinda L. Telli, MD

Panelists discuss how patients with HER2+ breast cancer frequently develop brain metastases, with recent pivotal trials such as HER2CLIMB and DESTINY-Breast03 demonstrating improved intracranial responses with newer agents such as tucatinib, and how trastuzumab deruxtecan leads to evolving standards of care (SOC) that now incorporate these targeted therapies alongside traditional local therapies.

5 experts are featured in this series

Proactive AE Management and Prophylactic Strategies With TADCs in Breast Cancer

ByNeil M. Iyengar, MD,Sara A. Hurvitz, MD, FACP ,Laura Huppert, MD,Anne P. O’Dea, MD,Melinda L. Telli, MD

Panelists discuss how trastuzumab deruxtecan’s (T-DXd's) key adverse events (AEs) include interstitial lung disease, neutropenia, and nausea/fatigue, emphasizing the importance of proactive monitoring, early intervention through coordinated multidisciplinary care, and comprehensive patient education with clear communication channels for reporting symptoms.

5 experts are featured in this series

Patient-Reported Outcomes and Quality of Life Data With T-DXd in HER2-(Ultra) Low mBC

ByNeil M. Iyengar, MD,Sara A. Hurvitz, MD, FACP ,Laura Huppert, MD,Anne P. O’Dea, MD,Melinda L. Telli, MD

Panelists discuss how trastuzumab deruxtecan (T-DXd) demonstrated favorable patient-reported outcomes and quality of life measures in HER2-low hormone receptor-positive metastatic breast cancer patients in DESTINY-Breast06, suggesting it could be a well-tolerated therapeutic option that maintains patients' daily functioning while providing clinical benefit.